Bo Mi Ku

3.8k total citations
58 papers, 1.9k citations indexed

About

Bo Mi Ku is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bo Mi Ku has authored 58 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Bo Mi Ku's work include Lung Cancer Treatments and Mutations (24 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (11 papers). Bo Mi Ku is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (11 papers). Bo Mi Ku collaborates with scholars based in South Korea, United States and Saudi Arabia. Bo Mi Ku's co-authors include Keunchil Park, Myung‐Ju Ahn, Jin Seok Ahn, Se‐Hoon Lee, Jong‐Mu Sun, Sang Soo Kang, Jiae Koh, Jinhyun Cho, Wan Sung Choi and Gyeong Jae Cho and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Bo Mi Ku

58 papers receiving 1.8k citations

Peers

Countries citing papers authored by Bo Mi Ku

Since Specialization

Citations

This map shows the geographic impact of Bo Mi Ku's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Mi Ku with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Mi Ku more than expected).

Fields of papers citing papers by Bo Mi Ku

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Mi Ku. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Mi Ku. The network helps show where Bo Mi Ku may publish in the future.

Co-authorship network of co-authors of Bo Mi Ku

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Mi Ku. A scholar is included among the top collaborators of Bo Mi Ku based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Mi Ku. Bo Mi Ku is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer 2023 ·Journal of Thoracic Oncology ·Hyun Ae Jung, Bo Mi Ku, Yeon Jeong Kim, Sehhoon Park, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Yoon‐La Choi, Sun Hye Shin, Byeong‐Ho Jeong, Sang‐Won Um, Hojoong Kim, Kyunga Kim, Myung‐Ju Ahn, Jingook Kim	37
2	Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study 2022 ·SHILAP Revista de lepidopterología ·Bo Mi Ku, (unknown), Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Yoon‐La Choi, Myung‐Ju Ahn	1
3	933MO Longitudinal monitoring of circulating tumor DNA from plasma in patients with curative resected stage IA-IIIA EGFR mutant non-small cell lung cancer 2022 ·Annals of Oncology ·M-J. Ahn, Hyun Ae Jung, Bo Mi Ku, (unknown), Seo‐Young Park, (unknown), SH Lee, (unknown), (unknown), H.K. Kim, (unknown), (unknown)	1
4	Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Kyung Hwan Kim, Hongryull Pyo, Hoyoung Lee, Dongryul Oh, Jae Myoung Noh, Yong Chan Ahn, Hong In Yoon, Hyowon Moon, Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Bo Mi Ku, Myung‐Ju Ahn, (unknown)	13
5	A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21) 2022 ·Journal of Thoracic Oncology ·Hyun Ae Jung, Miso Kim, Hae Su Kim, Joo-Hang Kim, Yoon Hee Choi, Jinhyun Cho, Ji Hyun Park, Keon Uk Park, Bo Mi Ku, Sehhoon Park, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	16
6	Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor 2022 ·Oncology ·Bo Mi Ku, Yeon Jeong Kim, Donghyun Park, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn, Jong‐Mu Sun	7
7	Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer 2021 ·BMB Reports ·Sehhoon Park, Chung Lee, Bo Mi Ku, (unknown), Woong‐Yang Park, Nayoung K. D. Kim, Myung‐Ju Ahn	6
8	Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model 2021 ·Nanomedicine Nanotechnology Biology and Medicine ·Jiae Koh, Sohyun Kim, Sang Nam Lee, Sunyoung Kim, Jung‐Eun Kim, (unknown), (unknown), (unknown), (unknown), Bo Mi Ku, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Siyoung Yang, Sang‐Jun Ha, Yong Taik Lim, Myung‐Ju Ahn	29
9	An increase of CD8+ T cell infiltration following recurrence is a good prognosticator in HNSCC 2020 ·Scientific Reports ·Yoon Kyoung So, Sun‐ju Byeon, Bo Mi Ku, Young Hyeh Ko, Myung‐Ju Ahn, Young‐Ik Son, Man Ki Chung	35
10	Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping 2020 ·In Vivo ·Joon Young Hur, Bo Mi Ku, Joonho Shim, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	15
11	The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors 2019 ·Clinical Cancer Research ·Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin	132
12	P2.14-61 Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer 2019 ·Journal of Thoracic Oncology ·Bo Mi Ku, Hyun Ae Jung, Jong‐Mu Sun, (unknown), Jin Seok Ahn, K. Park, M-J. Ahn	2
13	Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model 2018 ·PLoS ONE ·Bo Mi Ku, Moon Ki Choi, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	19
14	KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma 2017 ·Journal of Thoracic Oncology ·Jang Ho Cho, Bo Mi Ku, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	32
15	Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer 2016 ·Cancer Research and Treatment ·Min‐Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Keunchil Park, Young Lyun Oh, Min Eui Hong, (unknown), Young-Ik Son, Chung‐Hwan Baek, Myung‐Ju Ahn	21
16	AZD9291 overcomes T790 M-mediated resistance through degradation of EGFRL858R/T790M in non-small cell lung cancer cells 2016 ·Investigational New Drugs ·Bo Mi Ku, (unknown), Jiae Koh, Jong‐Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	13
17	A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non–Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib 2015 ·Clinical Cancer Research ·Ji Yun Lee, Jong‐Mu Sun, Sung Hee Lim, Hae Su Kim, Kwai Han Yoo, Ki Sun Jung, Haa‐Na Song, Bo Mi Ku, Jiae Koh, (unknown), Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	28
18	Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells 2014 ·Amino Acids ·Bo Mi Ku, Chang Hun Lee, Seon-Hyeong Lee, Soo‐Youl Kim	12
19	Caffeine-Mediated Inhibition of Calcium Release Channel Inositol 1,4,5-Trisphosphate Receptor Subtype 3 Blocks Glioblastoma Invasion and Extends Survival 2010 ·Cancer Research ·Sang Soo Kang, Kyung‐Seok Han, Bo Mi Ku, Yeon Kyung Lee, Jinpyo Hong, Hye Young Shin, Antoine G. Almonte, Dong Ho Woo, Daniel J. Brat, Eun Mi Hwang, Seung Hyun Yoo, Chun Kee Chung, Sung‐Hye Park, Sun Ha Paek, Eun Joo Roh, Sung Joong Lee, Jae‐Yong Park, Stephen F. Traynelis, C. Justin Lee	153
20	CHI3L1 (YKL‐40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells 2010 ·International Journal of Cancer ·Bo Mi Ku, Yeon Kyung Lee, Jinhyun Ryu, Joo Jeong, Jungil Choi, (unknown), Hye Young Shin, Dong Gyu Kim, Eun Mi Hwang, Jae Cheal Yoo, Jae‐Yong Park, Gu Seob Roh, Hyun Joon Kim, Gyeong Jae Cho, Wan Sung Choi, Sun Ha Paek, Sang Soo Kang	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact